Sign in

CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company

Dianthus Therapeutics, Inc. /DE/

Sign in to watch
Ticker
DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
929-999-4055
Business address
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Former names
Magenta Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$16,043,610
in 4 filings, $16.0M under 10b5-1 plans

Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Savitz Ryan −$11.2M EVP, CFO & CBO sold 100% of stake
  2. Randhawa Simrat −$2.5M EVP, Head of R&D sold 85% of stake
  3. CARR EDWARD −$2.0M CHIEF ACCOUNTING OFFICER sold 100% of stake
  4. Read Simon −$327K Director sold 100% of stake
Date Insider Transaction Shares Price Value Owned after
2019-06-07 Booth Bruce Director Grant or award · Stock Option (Right to Buy) +18,188 18,188
2019-06-07 Daniel Thomas O Director Grant or award · Stock Option (Right to Buy) +18,188 18,188
2019-06-07 BYERS BLAKE Director Grant or award · Stock Option (Right to Buy) +18,188 18,188
2019-06-07 Borisy Alexis Director Grant or award · Stock Option (Right to Buy) +18,188 18,188
2019-06-07 BONNEY MICHAEL W Director Grant or award · Stock Option (Right to Buy) +18,188 18,188
2019-03-20 Atlas Venture Fund X, L.P. 10% owner Other disposition −726,500 4,117,125
2019-03-20 Atlas Venture Fund X, L.P. 10% owner Other acquisition +14,245 14,245
2019-03-20 Atlas Venture Fund X, L.P. 10% owner Sale −14,245 $17.86 $254K 0
2019-03-20 Booth Bruce Director Other disposition −726,500 4,117,125
2019-03-20 Booth Bruce Director Other acquisition +14,245 14,245
2019-03-20 Booth Bruce Director Sale −14,245 $17.86 $254K 0
2019-02-05 ZDRAVESKI ZORAN See Remarks Grant or award · Stock Option (Right to Buy) +80,000 80,000
2019-02-05 DAVIS JOHN C. JR Chief Medical Officer Grant or award · Stock Option (Right to Buy) +70,000 70,000
2019-02-05 COOKE MICHAEL P. Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +64,000 64,000
2019-02-05 GARDNER JASON See Remarks Grant or award · Stock Option (Right to Buy) +182,900 182,900
2019-02-05 ISACSON CHRISTINA K. Chief Business Officer Grant or award · Stock Option (Right to Buy) +80,000 80,000
2019-01-02 Ryan Jason See Remarks Grant or award · Stock Option (Right to Buy) +329,379 329,379
2018-09-25 RONNEBERG AMY L Director Grant or award · Stock Option (Right to Buy) +52,244 52,244
2018-06-25 Atlas Venture Fund X, L.P. 10% owner Conversion +4,746,876 4,843,625
2018-06-25 Atlas Venture Fund X, L.P. 10% owner Conversion · Series A Preferred Stock −12,061,496 0

Page 21 of 24 · 470 trades